National Observatory of Children Hospitalized for Bronchiolitis

Study Overview
=================
Brief Summary
-----------------
This study is an observational, multicenter and prospective study for surveillance of case of hospitalised children for bronchiolitis associated or not to RSV or other viruses (isolated or associated with RSV)

Detailed Description
-----------------
The aim of this surveillance is to observe and describe the cases hospitalized for bronchiolitis in the 2023/2024 season in the context of routine immunization with Nirsevimab.

Official Title
-----------------
National Observatory of Children Hospitalized for Bronchiolitis

Conditions
-----------------
Bronchiolitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children under 12 months of age In one of the 6 study sites From October 15, 2023 For acute bronchiolitis defined according to current national and international recommendations Hospitalized from the pediatric emergency department. Exclusion Criteria: - Refusal to participate by patient relative or legal representative

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 12 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients hospitalized for bronchiolitis | Assessment of the number of hospitalized bronchiolitis in the context of routine immunization with Nirsevimab | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of RSV vs non-RSV associated to bronchiolitis hospitalizations | Assessment of proportion of RSV vs non- RSV associated bronchiolitis hospitalizations | 1 year | 
| Proportion of other viruses associated to bronchiolitis hospitalizations. | Assessment of the proportion of other viruses (isolated or associated with RSV) associated bronchiolitis hospitalizations | 1 year | 
| Proportion of patients immunized with Nirsevimab among children hospitalized for bronchiolitis | Description of immunization status with Nirsevimab of hospitalized patients for bronchiolitis overall (RSV+, RSV-) and other viruses (isolated or associated with RSV) | 1 year | 
| Proportion of demographics and clinical characteristics of patients hospitalized for bronchiolitis overall | Description of demographics (including immunization status with Nirsevimab) and clinical characteristics of patients hospitalized for bronchiolitis overall ( RSV+, RSV-) and other viruses (isolated or associated with RSV) | 1 year | 
| Proportion of demographics, clinical and viral characteristics of patients hospitalized for bronchiolitis requiring ventilation support | Description of demographics (including immunization status with Nirsevimab), clinical and viral characteristics of patients hospitalized for bronchiolitis requiring ventilation support | 1 year | 
| Length of hospital stay of children with bronchiolitis overall in France | Assesment of the duration of hospitalization for bronchiolitis overall (RSV+, RSV-) in France | 1 year | 
| Length of hospital stay of children with bronchiolitis in France according to immunization status with Nirsevimab | Assesment of the duration of hospitalization for bronchiolitis according to immunization status with Nirsevimab | 1 year |